TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.

Authors

Douglas Adkins

Washington University School of Medicine, St. Louis, MO

Douglas Adkins , Valerii Cheshuk , Julio Antonio Peguero , John J. Park , Antonio Lopez-Pousa , Willem Lybaert , Irene Brana , Bernard Doger , Frederic Triebel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.

First Author: Bernard Doger de Spéville

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with pembrolizumab and carboplatin as first-line treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC): A single-arm, phase 2 trial.

First Author: Jared Cohen

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Pembrolizumab (P) or P + chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state.

First Author: Danny Rischin

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Evaluation of ICI sensitivity for pembrolizumab in combination with anti-platelet therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC).

First Author: Karthik Chakravarthy